MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27 KIP1

Oncogene

Volumn 32, Issue 17, 2013, Pages 2239-2246

  Gomez Casares M T ^a   Garcia Alegria E ^b   Lopez Jorge C E ^a   Ferrandiz N ^b,e   Blanco, R ^b   Alvarez, S ^c   Vaque J P ^b,f   Bretones, G ^b   Caraballo, J M ^b   Sanchez Bailon P ^d   Delgado, M D ^b   Martin Perez J ^d   Cigudosa, J C ^c   Leon J ^a,b  

^a Hospital Universitario Dr Negrý n   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

^c Centro Nacional de Investigations Oncológicas   (Spain)

^d INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f IFIMAV   (Spain)

Author keywords

chronic myeloid leukemia; dasatinib; differentiation; imatinib; Myc; p27

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; DASATINIB; IMATINIB; MYC PROTEIN; UBIQUITIN PROTEIN LIGASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOID LEUKEMIA CELL; CONTROLLED STUDY; ERYTHROID CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BENZAMIDES; BETA-GLOBINS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; ERYTHROID CELLS; GENE EXPRESSION; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; PYRIMIDINES; S-PHASE KINASE-ASSOCIATED PROTEINS; THIAZOLES;

EID: 84876898096     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.246     Document Type: Article

References (47)

1. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264. (Pubitemid 44311039)
2. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22: 2755-2766.
3. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016. (Pubitemid 29276540)
4. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006; 16: 318-330. (Pubitemid 44311040)
5. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976-990.
6. Leon J, Ferrandiz N, Acosta JC, Delgado MD. Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis Cell Cycle 2009; 8: 1148-1157.
7. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
8. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996; 272: 877-880.
9. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267. (Pubitemid 351430863)
10. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10-17. (Pubitemid 30130220)
11. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-199. (Pubitemid 129500937)
12. Sutterluty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Muller U et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207-214. (Pubitemid 129500939)
13. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27(Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661-664.
14. Bretones G, Acosta JC, Caraballo JM, Ferrandiz N, Gomez-Casares MT, Albajar M et al. SKP2 oncogene is a direct MYC target gene and MYC downregulates p27(KIP1) through SKP2 in human leukemia cells. J Biol Chem 2011; 286: 9815-9825.
15. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164-172. (Pubitemid 29325745)
16. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7: 441-453. (Pubitemid 46823444)
17. Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008; 8: 341-350. (Pubitemid 351589698)
18. Kavalerchik E, Goff D, Jamieson CH. Chronic myeloid leukemia stem cells. J Clin Oncol 2008; 26: 2911-2915.
19. Albajar M, Gomez-Casares MT, Llorca J, Mauleon I, Vaque JP, Acosta JC et al. MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res 2011; 9: 564-576.
20. Delgado MD, Lerga A, Canelles M, Gomez-Casares MT, Leon J. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene 1995; 10: 1659-1665.
21. Acosta JC, Ferrandiz N, Bretones G, Torrano V, Blanco R, Richard C et al. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol 2008; 28: 7286-7295.
22. O'Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 2002; 53: 369-381. (Pubitemid 34177887)
23. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172-183. (Pubitemid 40314949)
24. Quintas-Cardama A, Cortes J. Molecular biology of bcr-Abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-1630.
25. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008; 14: 485-493.
26. Albajar M, Gutierrez P, Richard C, Rosa-Garrido M, Gomez-Casares MT, Steegmann JL et al. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett 2008; 270: 328-336.
27. Munoz-Alonso MJ, Acosta JC, Richard C, Delgado MD, Sedivy J, Leon J. p21Cip1 and p27Kip1 induce distinct cell cycle effects and differentiation programs in myeloid leukemia cells. J Biol Chem 2005; 280: 18120-18129. (Pubitemid 41389057)
28. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem 2000; 275: 39223-39230. (Pubitemid 32058940)
29. Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood 2000; 96: 1933-1939. (Pubitemid 30661080)
30. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG et al. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst 2008; 100: 926-939. (Pubitemid 351957515)
31. Gomez-Casares MT, Delgado MD, Lerga A, Crespo P, Quincoces AF, Richard C et al. Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells. Leukemia 1993; 7: 1824-1833. (Pubitemid 23347302)
32. Lerga A, Crespo P, Berciano M, Delgado MD, Canelles M, Cales C et al. Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. Cell Growth Differ 1999; 10: 639-654. (Pubitemid 29455728)
33. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 1995; 23: 1686-1690.
34. Schenone S, Brullo C, Musumeci F, Botta M. Novel dual Src/Abl inhibitors for hematologic and solid malignancies. Expert Opin Investig Drugs 2011; 19: 931-945.
35. Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011; 17: 1674-1683.
36. Rubbi L, Titz B, Brown L, Galvan E, Komisopoulou E, Chen SS et al. Global phosphoproteomics reveals crosstalk between Bcr-Abl and negative feedback mechanisms controlling Src signaling. Sci Signal 2011; 4: ra18.
37. Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S et al. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell 2007; 128: 281-294. (Pubitemid 46123510)
38. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6: 661-672. (Pubitemid 38579350)
39. Kossatz U, Dietrich N, Zender L, Buer J, Manns MP, Malek NP. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev 2004; 18: 2602-2607. (Pubitemid 39453099)
40. Andreu EJ, Lledo E, Poch E, Ivorra C, Albero MP, Martinez-Climent JA et al. BCRABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Cancer Res 2005; 65: 3264-3272. (Pubitemid 40524610)
41. Chen JY, Wang MC, Hung WC. Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells. Leuk Res 2009; 33: 1520-1524.
42. Agarwal A, Bumm TG, Corbin AS, O'Hare T, Loriaux M, VanDyke J et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008; 112: 1960-1970.
43. Hsieh FF, Barnett LA, Green WF, Freedman K, Matushansky I, Skoultchi AI et al. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. Blood 2000; 96: 2746-2754.
44. Rowley PT, Ohlsson-Wilhelm BM, Farley BA, LaBella S. Inducers of erythroid differentiation in K562 human leukemia cells. Exp Hematol 1981; 9: 32-37. (Pubitemid 11154346)
45. Roy S, Singh RP, Agarwal C, Siriwardana S, Sclafani R, Agarwal R. Downregulation of both p21/Cip1 and p27/Kip1 produces a more aggressive prostate cancer phenotype. Cell Cycle 2008; 7: 1828-1835. (Pubitemid 351988749)
46. Gomez-Casares MT, Vaque JP, Lemes A, Molero T, Delgado MD, Leon J. C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica 2004; 89: 241-243. (Pubitemid 38796503)
47. Lee TC, Ziff EB. Mxi1 is a repressor of the c-Myc promoter and reverses activation by USF. J Biol Chem 1999; 274: 595-606.